AR085090A1 - Formulacion transdermica de testosterona, metodo de tratamiento - Google Patents

Formulacion transdermica de testosterona, metodo de tratamiento

Info

Publication number
AR085090A1
AR085090A1 ARP120100241A ARP120100241A AR085090A1 AR 085090 A1 AR085090 A1 AR 085090A1 AR P120100241 A ARP120100241 A AR P120100241A AR P120100241 A ARP120100241 A AR P120100241A AR 085090 A1 AR085090 A1 AR 085090A1
Authority
AR
Argentina
Prior art keywords
weight
formulation
long chain
chain fatty
testosterone
Prior art date
Application number
ARP120100241A
Other languages
English (en)
Spanish (es)
Inventor
Arnaud Grenier
Dario N Carrara
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085090(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR085090A1 publication Critical patent/AR085090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP120100241A 2011-01-26 2012-01-25 Formulacion transdermica de testosterona, metodo de tratamiento AR085090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11152210 2011-01-26

Publications (1)

Publication Number Publication Date
AR085090A1 true AR085090A1 (es) 2013-09-11

Family

ID=44146428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100241A AR085090A1 (es) 2011-01-26 2012-01-25 Formulacion transdermica de testosterona, metodo de tratamiento

Country Status (28)

Country Link
US (2) US8895053B2 (https=)
EP (2) EP3072505B1 (https=)
JP (2) JP6012632B2 (https=)
KR (1) KR101877476B1 (https=)
CN (1) CN103327962B (https=)
AR (1) AR085090A1 (https=)
AU (1) AU2012210691B2 (https=)
BR (1) BR112013018951B1 (https=)
CA (1) CA2824941A1 (https=)
DK (2) DK2667851T3 (https=)
ES (2) ES2741744T3 (https=)
HR (2) HRP20160887T1 (https=)
HU (3) HUE027453T4 (https=)
IL (1) IL227454A (https=)
JO (1) JO3755B1 (https=)
LT (2) LT3072505T (https=)
MX (1) MX340259B (https=)
NO (1) NO2018034I1 (https=)
PL (2) PL2667851T3 (https=)
PT (2) PT3072505T (https=)
RS (2) RS54898B1 (https=)
RU (1) RU2613891C2 (https=)
SA (1) SA112330224B1 (https=)
SI (2) SI2667851T1 (https=)
TR (1) TR201909271T4 (https=)
TW (1) TWI564029B (https=)
WO (1) WO2012101016A1 (https=)
ZA (1) ZA201305665B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
PL4512390T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Wytwarzanie degareliksu
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
RU2699674C1 (ru) * 2015-09-30 2019-09-09 Фуджифилм Корпорэйшн Композиция для чрескожной абсорбции
JP7220473B2 (ja) * 2017-10-30 2023-02-10 帝國製薬株式会社 経皮投与製剤
EP3737374B1 (en) 2018-01-10 2024-04-03 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
WO2020010205A1 (en) 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN109700764B (zh) * 2019-02-20 2021-07-06 广东食品药品职业学院 双氢睾酮原位凝胶喷雾剂及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
DE69214818T2 (de) 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
EP0556034B2 (en) 1992-02-12 2004-07-21 Daikyo Gomu Seiko Ltd. A medical instrument
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
ATE534373T1 (de) * 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
BRPI0809124A8 (pt) * 2007-03-23 2015-11-24 Unimed Pharmaceuticals Llc Composições e métodos para tratamento de hipogonadismo pediátrico
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
MX2011011431A (es) 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2012024361A1 (en) * 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
KR20140063602A (ko) 2011-07-15 2014-05-27 훼링 비.브이. 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법

Also Published As

Publication number Publication date
BR112013018951A2 (pt) 2017-04-04
PL2667851T3 (pl) 2017-01-31
HUE027453T4 (hu) 2018-12-28
BR112013018951B1 (pt) 2020-03-10
PT3072505T (pt) 2019-07-04
CA2824941A1 (en) 2012-08-02
HRP20160887T1 (hr) 2016-09-23
IL227454A0 (en) 2013-09-30
MX2013008463A (es) 2013-10-03
LTPA2018516I1 (lt) 2018-11-12
DK3072505T3 (da) 2019-08-12
ZA201305665B (en) 2014-03-26
DK2667851T3 (en) 2016-07-25
JP6012632B2 (ja) 2016-10-25
RS59012B1 (sr) 2019-08-30
PL3072505T3 (pl) 2019-12-31
TW201309341A (zh) 2013-03-01
SI3072505T1 (sl) 2019-08-30
EP2667851A1 (en) 2013-12-04
HK1192719A1 (zh) 2014-08-29
EP2667851B1 (en) 2016-05-18
EP3072505A1 (en) 2016-09-28
JP2017019819A (ja) 2017-01-26
EP3072505B1 (en) 2019-06-12
RS54898B1 (sr) 2016-10-31
TWI564029B (zh) 2017-01-01
SI2667851T1 (sl) 2016-07-29
PT2667851T (pt) 2016-07-26
ES2586122T3 (es) 2016-10-11
HUE027453T2 (en) 2016-09-28
IL227454A (en) 2017-02-28
AU2012210691A1 (en) 2013-08-01
US20150110856A1 (en) 2015-04-23
NO2018034I1 (no) 2018-09-27
HRP20191216T1 (hr) 2019-10-18
KR20140041431A (ko) 2014-04-04
HUS1800036I1 (hu) 2018-09-28
RU2013133082A (ru) 2015-03-10
NZ613029A (en) 2014-03-28
ES2741744T3 (es) 2020-02-12
US20130295166A1 (en) 2013-11-07
RU2613891C2 (ru) 2017-03-21
SA112330224B1 (ar) 2015-02-22
JO3755B1 (ar) 2021-01-31
CN103327962B (zh) 2016-04-27
LT3072505T (lt) 2019-08-26
WO2012101016A1 (en) 2012-08-02
CN103327962A (zh) 2013-09-25
AU2012210691B2 (en) 2016-05-12
KR101877476B1 (ko) 2018-07-11
US8895053B2 (en) 2014-11-25
HUE044327T2 (hu) 2019-10-28
JP2014503565A (ja) 2014-02-13
MX340259B (es) 2016-07-04
TR201909271T4 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
AR085090A1 (es) Formulacion transdermica de testosterona, metodo de tratamiento
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
JP2014503565A5 (https=)
BR112014031837A2 (pt) formulações de progesterona
AR085927A1 (es) Composiciones farmaceuticas intranasales de benzodiazepina
RU2016141135A (ru) Трансдермальный крем
NZ610465A (en) Clevidipine emulsion formulations containing antimicrobial agents
AR087863A1 (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
EA200801602A1 (ru) Эмульсия
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
CR20120605A (es) Formulación tópica para un inhibidor de jak
JP2013515742A5 (https=)
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
WO2015184127A3 (en) Stable cannabinoid formulations
MX367097B (es) FORMULACION PARA ANTICUERPO ANTI-A4ß7.
ECSP13013028A (es) Cosmético
MX350636B (es) Inhibicion de irritacion sensorial durante el consumo de productos de tabaco no fumables.
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
BR112012031297A2 (pt) formulações de spray oral e métodos para administração de sildenafil
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
WO2013009800A3 (en) Compositions of alkylating agents and methods of treating skin disorders therewith
CO6592098A2 (es) Formulacion estable de mia/cd-rap

Legal Events

Date Code Title Description
FC Refusal